Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a presentation will be made at the annual European Society of Emergency Medicine (EuSEM) meeting to be held October 11thth to October 14th, 2015 at the Lingotto Congress Centre in Turin, Italy. The annual EuSEM is the largest meeting of emergency medicine practitioners in the world with over 2000 delegates in attendance and 90 countries represented.
The presentation marks the first time top-line results from the recently completed phase 3 study using sublingual sufentanil 30mcg tablets for the management of moderate to severe acute pain in outpatient abdominal surgery patients, or SAP301, will be revealed to the academic and scientific community. Data from the previously announced phase 2 bunionectomy trial will also be included. Both studies were multi-center, randomized, double-blind and placebo-controlled. (Original Source)
Shares of Acelrx Pharmaceuticals closed yesterday at $3.47. ACRX has a 1-year high of $9.32 and a 1-year low of $2.92. The stock’s 50-day moving average is $3.84 and its 200-day moving average is $3.98.
On the ratings front, Acelrx has been the subject of a number of recent research reports. In a report released yesterday, Cowen analyst Boris Peaker reiterated a Hold rating on ACRX. Separately, on the same day, Roth Capital’s Michael Higgins maintained a Buy rating on the stock and has a price target of $10.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Boris Peaker and Michael Higgins have a total average return of 21.9% and 6.2% respectively. Peaker has a success rate of 47.0% and is ranked #98 out of 3772 analysts, while Higgins has a success rate of 50.0% and is ranked #1235.
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in thedevelopment and commercialization of therapies for the treatment of acute pain.